First In Human Study of CX-801 in Advanced Solid Tumors
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 121
- Registration Number
- NCT06462794
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of Pittsburgh Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
First In Human Study of CX-2051 in Advanced Solid Tumors
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 124
- Registration Number
- NCT06265688
- Locations
- 🇺🇸
Carolina BioOncology Institute, PLLC, Huntersville, North Carolina, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, LLC, Nashville, Tennessee, United States
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT05387265
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸Virginia Cancer Specialist, Fairfax, Virginia, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 125
- Registration Number
- NCT04596150
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Los Angeles Hematology Oncology Medical, Los Angeles, California, United States
🇺🇸USC Norris Cancer Center, Los Angeles, California, United States
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 3
- Registration Number
- NCT03993379
- Locations
- 🇺🇸
Inova Dwight and March Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸Beacon Cancer Care, Coeur d'Alene, Idaho, United States
🇳🇱University Medical Center Groningen, Groningen, Netherlands
PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors
- First Posted Date
- 2018-10-15
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- CytomX Therapeutics
- Registration Number
- NCT03706274
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL
- Conditions
- Interventions
- First Posted Date
- 2018-06-01
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 133
- Registration Number
- NCT03543813
- Locations
- 🇬🇧
Beatson, West of Scotland Cancer Centre, Glasgow, United Kingdom
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇺🇸START Midwest, Grand Rapids, Michigan, United States
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 99
- Registration Number
- NCT03149549
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 300
- Registration Number
- NCT03013491
- Locations
- 🇬🇧
PROCLAIM Invetigative Site, Glasgow, United Kingdom
🇬🇧PROCLAIM Investigative Site, Newcastle upon Tyne, United Kingdom
🇪🇸PROCLAIM Investigative Ssite, Valencia, Spain